Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
Phase 2
Not yet recruiting
- Conditions
- Local Analgesia Via Nerve Block
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT06529432
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT06520488
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06516926
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Phase 3
Recruiting
- Conditions
- Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
- Interventions
- Drug: Herombopag placebo tablets
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 101
- Registration Number
- NCT06507436
- Locations
- 🇨🇳
Zhongshan Hospital, affiliated with Fudan University, Shanghai, Shanghai, China
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung Cancer With HER2- Mutations
- Interventions
- Drug: Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06430437
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
Phase 3
Not yet recruiting
- Conditions
- Gout With Hyperuricemia in Adults
- Interventions
- Drug: HR091506 tablets + placebo of febuxostat tablets
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 434
- Registration Number
- NCT06414837
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- HER2 Expression / Amplification in Patients With Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT06413745
- Locations
- 🇨🇳
Zhongshan Hospital，Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06408948
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Phase 1
- Conditions
- Advanced KRAS G12D Mutant Solid Tumors
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT06385678
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Comparison of HR011408 and NovoRapid® in Subjects With Diabetics
Phase 1
Recruiting
- Conditions
- Diabetes
- Interventions
- Drug: HR011408 injection; HR011408 injection PlaceboDrug: NovoRapid®; HR011408 injection PlaceboDrug: HR011408 injection Placebo; HR011408 injection
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06375031
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath